The Rise of Plant-Based Health and Wellness HempFusion (STOCK:CBD) Uniquely Positioned to Dominate Potential $16 Billion Market

Top Reasons to Consider HempFusion Now

  1. HempFusion is one of a few select companies to offer US FDA drug listed topicals.(1)
  2. Analysts at New Frontier Data projects the US CBD consumer market could reach $26.4 Billion by 2025.(2)
  3. HempFusion has no debt, and has the second largest cash position in the sector.(3)
  4. The company has established a proven team, with established relationships to significantly scale the business across several strategic channels including; Big box, e-Commerce
  5. It’s distributing its family of brands — HempFusion, Probulin Probiotics, Biome Research, and HF Labs, to approximately 4,000 retailers including Amazon, Whole Foods, Costco, Kroger’s, CVS Pharmacy, and Vitamin Shoppe.
  6. The company’s products meet the compliance standards for larger national retailers, which could lead to substantial growth in Big Box stores.
  7. HempFusion is also a board member of the US Hemp Roundtable.(3)
  8. The company is well-positioned in the CBD gummies market – which could be worth approximately $6.94 billion by 2025, according to Grand View Research.(4)
  9. One of a select group of CBD companies sponsoring and participating in the largest human liver toxicology study on CBD with ValidCare
  10. The Company is about to significantly bolster its e-Commerce platform and marketing initiatives heading into 2021

CBD is seeing MONUMENTAL demand, creating INCREDIBLE opportunity for HempFusion (STOCK:CBD) – one of a select few companies to offer US FDA drug listed topicals.

Here’s why…

Over the last year, total sales of such consumer CBD products just in the U.S. came in at approximately $1.2 billion, according to Nielsen Global Connect.(5)

But that’s just the start.

With consumers becoming far more dependent on CBD with increased stress and anxiety with the pandemic, analysts at Nielsen say sales could reach $1.7 billion to $2 billion just this year.(5)

Nielsen also estimates that by 2025, CBD products could generate approx. $6.9 billion in sales.(5)

But that may be a low estimate.

Analysts at Cowen say sales could reach $16 billion by 2025 with health and wellness products leading the way – and with beverage, food, and beauty playing a big role.(6)

Coupled with rapidly changing consumer attitudes toward CBD, and sizable demand from consumers, retailers can’t even stock shelves fast enough, including Neiman Marcus, Sephora, Vitamin Shoppe, Kroger, Barney’s DSW, Sephora, CVS, American Eagle, and Walgreen’s.

Better yet, legalization is seeing broad support in the U.S.

  • A Pew Research Center survey found that 67% of the US supports legalization.(7)
  • A Gallup survey found that 66% of Americans are in favor of legalization. That’s up from just 60% in 2016.  On top of that, 14% of Americans now use CBD products.(8)

All of this could be a SIGNIFICANT catalyst for HempFusion (STOCK:CBD).

With no debt, and the second largest cash position in the sector, HempFusion is a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition.

At the moment, it distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research, and HF Labs, to approximately 4,000 retailers across all 50 states of the United States and select international locations.

Retailers including:

Built on a foundation of regulatory compliance and human safety, HempFusion’s diverse product portfolio comprises 46 SKUs including tinctures, proprietary FDA Drug Listed Over the Counter (OTC) Topicals, Doctor/Practitioner Lines and more.

HempFusion is also a board member of the US Hemp Roundtable – a coalition of leading hemp companies and organizations committed to safe products, and the advancement the industry responsible manner.

Plus, HempFusion’s wholly-owned subsidiary, Probulin Probiotics is one of the fastest-growing probiotics companies in the United States according to SPINs reported data.

Major Differentiating Factor: HempFusion is Also One of a Select Few CBD Companies to Offer US FDA Drug Listed Topicals

FDA Drug Listed OTC topical products allow for substantiated health claims, allowing for even greater trust among millions of potential consumers.

Plus, the company’s products meet the compliance standards for larger national retailers, which could lead to substantial growth in Big Box stores.

Top OTC products include:

  • OTC Pain Products, which positions the company to capitalize on a potential $13.3 billion global topical pain relief market.
  • OTC Eczema Products, which positions the company to capitalize on a potential $13.6 billion global dermatitis industry.
  • OTC Acne and Aging/Beauty Products, which positions the company to capitalize on a potential $1.08 trillion global personal care, beauty, and anti-aging market.
  • OTC Wound Heal First Aid Products, which positions the company to capitalize on a $650 million market opportunity.

HempFusion (STOCK:CBD) Has Direct Access to $7 Billion Global Market

The company’s Probulin line addresses a broad set of consumers, offering daily care, women’s health, total care, and children’s products with probiotics and digestive enzymes.

That gives the company access to a potential $7 billion market, and steady growth of 24% through 2024. All thanks to research that shows a strong relationship between gut flora (or gut microbiota – the micro-organisms including bacteria, archaea, and fungi that live in the digestive track of humans and other animals) and our health.

The best part – HempFusion’s Probulin may allow the company to enter retailers that may not currently carry CBD products, which may establish, develop, and build relationships.

Helping, the CBD Boom is Exploding All Around the World

In Europe, says the Brightfield Group, the CBD market generated $318 million in 2018. That number is expected to grow by over 400% by 2023.(10)

“CBD is just starting to take hold in Europe, with both product availability and consumer awareness still quite limited. This is a great opportunity for developed brands to enter and expand through Europe with far less competition than we’re seeing in the U.S.,” wrote Brightfield Managing Director Bethany Gomez.(10)

Canada is seen as one of the world leaders in the Medicinal Cannabis industry and also provides a relatively large singular market with a population of approximately 37 million.

The Latin America cannabis market is on pace to be one of the most exciting in the world.  In fact, it has the potential to become one of the largest markets in the world with an estimated value of $9.8 billion, according to New Frontier Data.(11)

That’s creating even more opportunity for HempFusion.

At the moment, HempFusion and Probulin probiotic products are selling across Europe (Ireland & UK), and Probulin has purchase orders and/or is selling in the Middle East, South Korea, China, Mexico, and India.

HempFusion Seeing Strong Growth with Medical Professional Relationships

HempFusion Also Seeing Strong Growth with CBD Gummies

The company is well-positioned in the CBD gummies market, too.

A market that could be worth $6.94 billion by 2025, according to Grand View Research.(12)

HempFusion launched its convenience strategy in July 2020 to distribute its family of brands. This includes the upcoming launch of HempFusion’s 10mg Plant-Based CBD Vegan Gummies.

HempFusion Also Has Proven Leadership with Strong Results

Successful companies tend to possess common traits, and one of those traits is a strong management team.  HempFusion has that ground covered with extensive leadership, finance, legal, CPG, governance, and M&A experience that can penetrate major channels, including Big-Box, Convenience, Natural, and Doctor/Practitioner.

DR. JASON MITCHELL, N.D.
CHIEF EXECUTIVE OFFICER

Dr. Mitchell is a naturopathic doctor and has developed over 300 products as the Chief Science Officer at Country Life Vitamins before its acquisition by Kikkoman’s in 2006. Jason maintains a substantial retailer rolodex developed over a 20+ year career.

JON VISSER
CHIEF REVENUE OFFICER

25+ years’ experience driving CPG sales in major retail channels (Big Box + Convenience + Club). Directed a national sales team for Abbott Laboratories, and has worked with every single large US retailer over his 25+ year career. Jon is an expert in introducing new innovative products into traditional sales channels. Mr. Visser has the track record, network and product knowledge to significantly expand HempFusion’s distribution.

OLA LESSARD
CHIEF MARKETING OFFICER

Developed significant retailer relationships while at Barlean’s, one of the most successful supplement brands in America. Ms. Lessard was responsible for overseeing the strategic entry of Barlean’s, a company with over 100+ total SKU’s, into the CBD category. Ms. Lessard is the President of the US Hemp Roundtable representing HempFusion. 25+ years’experience branding products to drive sales and build long-term brand loyalty.

NANCY ANGELINI
DIRECTOR OF DOCTOR/PRACTITIONER

Ms. Angelini has 25+ years’ experience as a licensed practitioner, traveling the United States as a lecturer, product manager, and opening doors to the largest doctor/practitioner networks in America. Substantial relationships and sales rolodex in the doctor/practitioner channel. Over 1500 natural health and healing lectures completed in the US and abroad.

Along with the management team is a strong financial team.

DANIEL BRODY,
CHIEF COMMERCIAL OFFICER

  • $710,000,000 raised for the Cannabis and CBD sector in the past 6 years including numerous IPO’s
  • Deep and established relationships with major brokerage firms and exchanges

BRUCE VALENTINE, Jr.
CHIEF FINANCIAL OFFICER

  • Helped grow revenue significantly while CFO of Otter Products (Once ranked as one of the fastest-growing private companies in the US)
  • 20 years of senior financial management and leadership expertise
  • Served as CFO of premium desserts maker Steven-Robert Originals,
  • LLC from 2016 to 2019
  • CFO of the Year Award Recipient

With pending FDA regulation looming, it is believed that only a few well capitalized companies will emerge as leaders and dominate this dynamic sector.

The Top 12 Reasons to Consider HempFusion (STOCK:CBD) Immediately

  1. HempFusion is one of a few select companies to offer US FDA drug listed topicals.
  2. Analysts at Cowen say CBD sales could reach $16 billion by 2025 with health and wellness products leading the way
  3. HempFusion has no debt, and has the second largest cash position in the sector.
  4. It’s distributing its family of brands — HempFusion, Probulin Probiotics, Biome Research, and HF Labs, to approximately 4,000 retailers including Amazon, Whole Foods, Costco, Kroger’s, CVS Pharmacy, and Vitamin Shoppe.
  5. The company’s products meet the compliance standards for larger national retailers, which could lead to substantial growth in Big Box stores.
  6. Its OTC Pain Products positions the company to capitalize on a potential $13.3 billion global topical pain relief market.
  7. Its OTC Eczema Products, positions the company to capitalize on a potential $13.6 billion global dermatitis industry.
  8. Its OTC Acne and Aging/Beauty Products positions the company to capitalize on a potential $1.08 trillion global personal care, beauty, and anti-aging market.
  9. At the moment, its HempFusion and Probulin probiotic products are selling across Europe (Ireland & UK), and Probulin has purchase orders and/or is selling in the Middle East, South Korea, China, Mexico, and India.
  10. HempFusion is also a board member of the US Hemp Roundtable.
  11. Its wholly-owned subsidiary, Probulin Probiotics is one of the fastest-growing probiotics companies in the United States according to SPINs reported data.
  12. The company is well-positioned in the CBD gummies market – which could be worth approximately $6.94 billion by 2025, according to Grand View Research.

Legal Disclosure


This website / media webpage is owned, operated and edited by TD Media LLC. Any wording found on this website / media webpage or disclaimer referencing to “I” or “we” or “our” or “TD Media” refers to TD Media LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote small public companies. By reading our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website / media webpage.

We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website / media webpage are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. TD Media business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our Websites, Email, SMS, Push Notifications, Influencers, Social Media Postings, Ticker Tags, Press Releases, Online Interviews, Podcasts, Videos, Audio Ads, Banner Ads, Native Ads, Responsive Ads. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors

We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, TD Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.

Pursuant to an agreement between TD Media LLC and Winning Media LLC, TD Media LLC has been hired for a period beginning on 11/19/20 and ending on 12/17/20 to publicly disseminate information about (CBD) via digital communications. We have been paid one hundred thousand USD via bank wire transfer. We own zero shares of (CBD).